149 related articles for article (PubMed ID: 37951218)
1. Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.
Chen SY; Duan XT; Li HF; Peng L; Wang ZQ; Xu GQ; Hua YJ; Zou X; You R; Ouyang YF; Liu YP; Gu CM; Yang Q; Jiang R; Zhang MX; Lin M; Xie YL; Lin C; Ding X; Xie RQ; Duan CY; Zhang WJ; Huang PY; Chen MY
Cell Rep Med; 2023 Nov; 4(11):101279. PubMed ID: 37951218
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
3. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
[TBL] [Abstract][Full Text] [Related]
4. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract][Full Text] [Related]
5. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
Guo SS; Yang JH; Sun XS; Liu LZ; Yang ZC; Liu LT; Liu SL; Li XY; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Liang YJ; Jia GD; Zhao C; Chen QY; Tang LQ; Mai HQ
Eur J Cancer; 2023 Nov; 194():113336. PubMed ID: 37801967
[TBL] [Abstract][Full Text] [Related]
6. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
7. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
You R; Liu YP; Lin M; Huang PY; Tang LQ; Zhang YN; Pan Y; Liu WL; Guo WB; Zou X; Zhao KM; Kang T; Liu LZ; Lin AH; Hong MH; Mai HQ; Zeng MS; Chen MY
Int J Cancer; 2019 Nov; 145(10):2873-2883. PubMed ID: 31044420
[TBL] [Abstract][Full Text] [Related]
8. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
[TBL] [Abstract][Full Text] [Related]
9. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
Li XY; Luo DH; Guo L; Mo HY; Sun R; Guo SS; Liu LT; Yang ZC; Yang JH; Qiu F; Sun XS; Wang P; Liu Q; Li JB; Tang QN; Lin C; Yang Q; Liu SL; Liang YJ; Jia GD; Wen DX; Guo CY; Yan JJ; Zhao C; Chen QY; Tang LQ; Mai HQ
J Clin Oncol; 2022 Apr; 40(11):1163-1173. PubMed ID: 34990291
[TBL] [Abstract][Full Text] [Related]
10. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.
Liang YJ; Chen QY; Xu JX; Liu XF; Xia JC; Liu LT; Guo SS; Song B; Wang P; Li JB; Liu Q; Mo HY; Guo L; Sun R; Luo DH; He J; Liu YN; Nie CP; Tang LQ; Li J; Mai HQ
Eur J Cancer; 2023 Sep; 191():112965. PubMed ID: 37540921
[TBL] [Abstract][Full Text] [Related]
12. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
You R; Zou X; Ding X; Zhang WJ; Zhang MX; Wang X; Xu HS; Liu YL; Ouyang YF; Duan CY; Gu CM; Wang ZQ; Liu YP; Hua YJ; Huang PY; Chen MY
Med; 2022 Oct; 3(10):664-681.e6. PubMed ID: 36041429
[TBL] [Abstract][Full Text] [Related]
14. Effects of Epstein-Barr virus viral load and different treatment modality for stage III nasopharyngeal carcinoma.
Twu CW; Wang WY; Tsou HH; Liu YC; Jiang RS; Liang KL; Lin PJ; Lin TY; Chen HH; Lin JC
Head Neck; 2020 Aug; 42(8):1765-1774. PubMed ID: 32011052
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
You R; Liu YP; Huang PY; Zou X; Sun R; He YX; Wu YS; Shen GP; Zhang HD; Duan CY; Tan SH; Cao JY; Li JB; Xie YL; Zhang YN; Wang ZQ; Yang Q; Lin M; Jiang R; Zhang MX; Hua YJ; Tang LQ; Zhuang AH; Chen QY; Guo L; Mo HY; Chen Y; Mai HQ; Ling L; Liu Q; Chua MLK; Chen MY
JAMA Oncol; 2020 Sep; 6(9):1345-1352. PubMed ID: 32701129
[TBL] [Abstract][Full Text] [Related]
16. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.
Zhou H; Lu T; Guo Q; Chen Y; Chen M; Chen Y; Lin Y; Chen C; Ma L; Xu Y; Lin S; Pan J
Cancer Med; 2020 Apr; 9(8):2732-2741. PubMed ID: 32090498
[TBL] [Abstract][Full Text] [Related]
18. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
[TBL] [Abstract][Full Text] [Related]
19. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
20. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]